The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical staging

<p>Abstract</p> <p>Background</p> <p>In intestinal epithelium, tyrosine kinase receptor Ephrin B3 (Eph B3) maintains the architecture of the crypt-villus axis by repulsive interaction with its ligand ephrin-B1. While loss of Eph B3 is linked to colorectal cancer initiat...

Full description

Bibliographic Details
Main Authors: Schauer Matthias C, Stoecklein Nikolas H, Theisen Joerg, Kröpil Feride, Baldus Stephan, Hoelscher Arnulf, Feith Markus, Bölke Edwin, Matuschek Christiane, Budach Wilfried, Knoefel Wolfram
Format: Article
Language:English
Published: BMC 2012-05-01
Series:European Journal of Medical Research
Subjects:
Online Access:http://www.eurjmedres.com/content/17/1/10
id doaj-48d78004090548008d237a2b7799b111
record_format Article
spelling doaj-48d78004090548008d237a2b7799b1112020-11-25T00:13:46ZengBMCEuropean Journal of Medical Research2047-783X2012-05-011711010.1186/2047-783X-17-10The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical stagingSchauer Matthias CStoecklein Nikolas HTheisen JoergKröpil FerideBaldus StephanHoelscher ArnulfFeith MarkusBölke EdwinMatuschek ChristianeBudach WilfriedKnoefel Wolfram<p>Abstract</p> <p>Background</p> <p>In intestinal epithelium, tyrosine kinase receptor Ephrin B3 (Eph B3) maintains the architecture of the crypt-villus axis by repulsive interaction with its ligand ephrin-B1. While loss of Eph B3 is linked to colorectal cancer initiation, overexpression of Eph B3 in cancer cell lines inhibits growth and induces functional changes with decreased mesenchymal and increased epithelial markers. In order to study this tumor suppressor activity of Eph B3 in esophageal adenocarcinoma we analyzed the simultaneous expression of Eph B3 and E-cadherin in both the healthy esophagus and in Barrett’s carcinoma.</p> <p>Methods</p> <p>Simultaneous expression of Eph B3 and E-cadherin was investigated in samples from 141 patients with Barrett’s carcinoma and from 20 healthy esophagi using immunhistology and quantitative PCR. Results from healthy squamous epithelium, Barrett’s metaplasia and staging-specific esophageal adenocarcinoma were correlated.</p> <p>Results</p> <p>A significantly reduced E-cadherin mRNA expression could be detected in adenocarcinoma compared to dysplasia. The immunhistological activity of E-cadherin and Eph B3 was reduced in adenocarcinoma compared to dysplasia or healthy esophageal mucosa. The intracellular E-cadherin distribution changed significantly from the cytoplasm to the membrane, when the Eph receptor was simultaneously expressed. Simultaneous expression of E-cadherin and Eph B3 showed a significant inverse correlation to tumor stage.</p> <p>Conclusions</p> <p>We present novel evidence of the tumor suppressor activity of Eph B3 in esophageal adenocarcinoma possibly due to the impact on redistribution of cellular E-cadherin to the membrane. Our results suggest that this effect might play a role in the dysplasia-adenocarcinoma sequence, the infiltrative growth pattern and the development of lymph node metastases.</p> http://www.eurjmedres.com/content/17/1/10E-cadherinEphrin B3 receptorEsophageal adenocarcinomaBarrett’s metaplasia
collection DOAJ
language English
format Article
sources DOAJ
author Schauer Matthias C
Stoecklein Nikolas H
Theisen Joerg
Kröpil Feride
Baldus Stephan
Hoelscher Arnulf
Feith Markus
Bölke Edwin
Matuschek Christiane
Budach Wilfried
Knoefel Wolfram
spellingShingle Schauer Matthias C
Stoecklein Nikolas H
Theisen Joerg
Kröpil Feride
Baldus Stephan
Hoelscher Arnulf
Feith Markus
Bölke Edwin
Matuschek Christiane
Budach Wilfried
Knoefel Wolfram
The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical staging
European Journal of Medical Research
E-cadherin
Ephrin B3 receptor
Esophageal adenocarcinoma
Barrett’s metaplasia
author_facet Schauer Matthias C
Stoecklein Nikolas H
Theisen Joerg
Kröpil Feride
Baldus Stephan
Hoelscher Arnulf
Feith Markus
Bölke Edwin
Matuschek Christiane
Budach Wilfried
Knoefel Wolfram
author_sort Schauer Matthias C
title The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical staging
title_short The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical staging
title_full The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical staging
title_fullStr The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical staging
title_full_unstemmed The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical staging
title_sort simultaneous expression of both ephrin b3 receptor and e-cadherin in barrett`s adenocarcinoma is associated with favorable clinical staging
publisher BMC
series European Journal of Medical Research
issn 2047-783X
publishDate 2012-05-01
description <p>Abstract</p> <p>Background</p> <p>In intestinal epithelium, tyrosine kinase receptor Ephrin B3 (Eph B3) maintains the architecture of the crypt-villus axis by repulsive interaction with its ligand ephrin-B1. While loss of Eph B3 is linked to colorectal cancer initiation, overexpression of Eph B3 in cancer cell lines inhibits growth and induces functional changes with decreased mesenchymal and increased epithelial markers. In order to study this tumor suppressor activity of Eph B3 in esophageal adenocarcinoma we analyzed the simultaneous expression of Eph B3 and E-cadherin in both the healthy esophagus and in Barrett’s carcinoma.</p> <p>Methods</p> <p>Simultaneous expression of Eph B3 and E-cadherin was investigated in samples from 141 patients with Barrett’s carcinoma and from 20 healthy esophagi using immunhistology and quantitative PCR. Results from healthy squamous epithelium, Barrett’s metaplasia and staging-specific esophageal adenocarcinoma were correlated.</p> <p>Results</p> <p>A significantly reduced E-cadherin mRNA expression could be detected in adenocarcinoma compared to dysplasia. The immunhistological activity of E-cadherin and Eph B3 was reduced in adenocarcinoma compared to dysplasia or healthy esophageal mucosa. The intracellular E-cadherin distribution changed significantly from the cytoplasm to the membrane, when the Eph receptor was simultaneously expressed. Simultaneous expression of E-cadherin and Eph B3 showed a significant inverse correlation to tumor stage.</p> <p>Conclusions</p> <p>We present novel evidence of the tumor suppressor activity of Eph B3 in esophageal adenocarcinoma possibly due to the impact on redistribution of cellular E-cadherin to the membrane. Our results suggest that this effect might play a role in the dysplasia-adenocarcinoma sequence, the infiltrative growth pattern and the development of lymph node metastases.</p>
topic E-cadherin
Ephrin B3 receptor
Esophageal adenocarcinoma
Barrett’s metaplasia
url http://www.eurjmedres.com/content/17/1/10
work_keys_str_mv AT schauermatthiasc thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT stoeckleinnikolash thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT theisenjoerg thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT kropilferide thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT baldusstephan thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT hoelscherarnulf thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT feithmarkus thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT bolkeedwin thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT matuschekchristiane thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT budachwilfried thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT knoefelwolfram thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT schauermatthiasc simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT stoeckleinnikolash simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT theisenjoerg simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT kropilferide simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT baldusstephan simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT hoelscherarnulf simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT feithmarkus simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT bolkeedwin simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT matuschekchristiane simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT budachwilfried simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
AT knoefelwolfram simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging
_version_ 1725393223620231168